Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

Nerandomilast slowed lung function decline in people with IPF and PPF after a year of treatment, according to data from two ...

Which cancer drug developers are attractive takeover targets? We asked Seeking Alpha analysts BioCGT Investor, ALLKA Research and Zach Hartman for their picks. BioCGT Investor: Cardiff Oncology ...

Terence M. Williams, MD, PhD, discussed the phase 1 DINOMITE trial of radiation therapy and papaverine in rectal cancer at ...

Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma ...

Among patients with chronic hypoparathyroidism, palopegteriparatide improved skeletal dynamics and renal function at 2 years, according to new data from the PaTHway trial. As Healio previously ...

Sanjay Goel, MD, MS, professor of medicine at Robert Wood Johnson Medical School and medical oncologist at Rutgers Cancer Institute, anticipates groundbreaking data at the American Society of Clinical ...

A groundbreaking new drug called zilebesiran has shown that just one injection every six months, when added to standard pills, can significantly lower blood pressure by 4 to 12 points depending on the ...

An updated framework for addressing traumatic brain injury places the focus on the acute phase, while considering internal, external and modifying factors that influence outcomes from these events, ...

Rocket Pharmaceuticals shares plummeted 60% Tuesday after the firm said it halted a study of a gene-therapy drug for Danon ...

As the World Health Organization initiates a new agreement for coordinating global responses to future pandemics, the future ...